Type

Range

Units

Status

Start Date

End Date

Financing

Study Design

Keywords

Labels

Brief description/objective

A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited. Preclinical in vitro studies have demon-strated a synergism of immunotherapy with PD(L)1- targeting monoclonal antibodies and gemcitabine ad-ministered in different tumors models and ongoing clin-ical studies showed encouraging results. This may represent a safe and effective therapy for patients who relapsed or did not respond to standard therapies.